Changing Trend: Magic Bullets to Designed Multiple Ligands (DMLs)

The concept of selective inhibitors (Magic Bullets) one drug-one disease is no more an ideal in drug discovery. Knocking down one protein target is not enough to treat complex diseases like cancer. If we knock down multiple targets in a biological pathway of a disease with Designed Multiple Ligands (DMLs), we may expect improved efficacy. The trend in recent developments in anticancer drug discovery shifting towards a multi-target approach. One good example is recent wave of FDA approvals, "lapatinib" a dual EGFR and Her-2/neu kinase inhibitor. The other one “dasatanib” a multi kinase inhibitor and many more.

Pharmaceutical "GOLD RUSH"

At last spring ACS meeting, I attended for BMS-Smissman award talk by a renowned scientist Bruce E. Mayanoff. His talk related to the true life stories in drug discovery, which also appeared in J. Med. Chem., ASAP. His observations are certainly true in industry. Nowadays, scientists like Bruce Maryanoff kind of attitude are very rare. Modern scientists have more faith on fast track drug discovery by process of doing it. No focus on real medical need, only rush..."GOLD RUSH" following behind each other. Good science leads to best used drugs. Read more on this topic at Org Prep Daily as well.

Inverse In Silico Screening for Identification of Kinase Inhibitor Targets

Nice article about in silico prediction of targets of a kinase inhibitor, which immensely facilitate and accelerate drug development. Using a virtual inverse screening approach, where single compounds are docked into protein structures from a database, to identify new targets for known inhibitors.

Prajapalanalo Information Technology

I received one e-mail from my brother informing about his latest book accepted for publication in Telugu script entitled "Prajapalanalo Information Technology" (Emesco Publishers). I read the introduction, where the author expressed about the impotance of utilizing information technology by governments.

Modular Enhancement of Nature's Diversity

I saw a publication from Prof.Miller's group on Modular Enhancement of Nature's Diversity (MEND) appeared in Org.Lett. 9 (15), 2923, 2007. Chemists especially who are working in natural products research will enjoy reading this article.

Drug Discovery and Synthesis

As this blog title you see "SAMSLESHANA" means Synthesis. I would like to write about some thing related to drug design, synthesis related articles and published in the form of patents or in journals. Visitors likely to enjoy reading blogs with new information on "Drug Discovery and Synthesis"